Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Sponsor: Allergan
Terminated
The Relamorelin program is being terminated solely based on a business decision
Other terminated trials from Allergan
Other Diabetes Mellitus trials with similar outcome
This PHASE3 trial investigates Diabetes Mellitus and Gastroparesis and is currently terminated or withdrawn. Allergan leads this study, which shows 20 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
20 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 15 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jun 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Jul 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Feb 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .